STERIALS

Leveraging its proprietary technology, the company will develop and commercialize therapeutic drug and device implants for chronic diseases with high unmet medical needs, such as small drug implants to address drug non-adhesion in type 2 diabetes patients and implantable artificial vision devices to provide useful artificial vision to the visually impaired.